The effectiveness of omeprazole versus lansoprazole along with amoxillicin and clarithromycin in Turkish population with duodenal ulcer

Minerva Gastroenterologica e Dietologica

Volumn 49, Issue 2, 2003, Pages 147-153

  Ormeci N ^a,f   Sarioglu M ^a   Sandikci M ^b   Ozutemiz O ^c   Boztas G ^d   Uner E ^e   Elhan, A H ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e ANKARA NUMUNE HOSPITAL   (Turkey)

^f NONE   (Turkey)

Author keywords

Anti ulcer agents; Duodenal ulcer; Omeprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENUM ULCER; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; STOMACH ACID SECRETION; TURKEY (REPUBLIC); ULCER HEALING; VERTIGO;

EID: 0347598156     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bruley Des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche PJ. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994;8:309-14.
2. Furuta T, Shiari N, Takashima M, Xiao F, Hanai H, Sugimura H et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter Pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69:158-68.
3. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet 1996;31:9-28.
4. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22:266-80.
5. Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G et al. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. Helicobacter 1998;3:195-201.
6. Ekstrom P, Carling L, Unge P, Anker-Hansen O, Sjostedt S, Sellstrom H. Lansoprazole versus omeprazole in active duodenal a double-blind, randomized, comparative study. Scand J Gastroenterol 1995;30:210-5.
7. Gupta VK, Dhar A, Srinivasan S, Rattan A, Sharma PM. Eradication of H. Pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Am J Gastroenterol 1997;92:1140-2.
8. Konturek PC, Konturek SJ. Role of Helicobacter pylori infection in gastro-duodenal secretion and in pathogenesis of peptic ulcer and gastritis. J Physiol Pharmacol 1994;45:333-50.
9. Lamouliatte H. Effect of lansoprazole on Helicobacter pylori. Clin Ther 1993;15:32-6.
10. Miwa H, Ohkura R, Murai T, Nagara A, Yamada T, Ogihara T et al. Effectiveness of omeprazole-amo-xicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. Helicobacter 1998;3:132-8.
11. Stedman CA, Barclay ML. Review article: Comparison of the pharmacokinetics acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78.
12. Dammann HG, Fuchs W, Richter G, Burkhardt F, Wolf N, Walter ATH. Lansoprazole versus omeprazole. Influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997;11:359-64.
13. Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm 1996;53:1401-15.
14. Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P, the Lansoprazole Study Group. Double-blind comparison of lansoprazole, ranitidine and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol 1994;89:1191-200.
15. Hawkey JC, Long GR, Bardhan DK, Wormsley GK, Cochran MK, Christian J et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993;34:1458-62.
16. + ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
17. Bardhan KD, Ahlberg J, Hislop SW, Lindholmer C, Long Gr, Morgan GA et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 1994;8:215-20.
18. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.
19. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7:661-5.
20. Bardhan KD, Crowe J, Thompson RP, Trewby PN, Keeling PN, Weir D et al. Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 1999;13:827-32.
21. Dobrilla G, Piazzi L, Fiocca R. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. Clin Ther 1999;21:1321-33.
22. Petite JP, Slama JL, Licht H, Lemerez M, Coste T, Andrieu J et al. Comparison du lansoprazole (30 mg) et de l'omèprazole (20 mg) dans le traitement de l'ulcère duodenal. Gastroenterol Clin Biol 1993;17:334-40.
23. Florent C. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. Clin Ther 1993;15:14-21.
24. Miwa H, Nagahara A, Sato K, Ohkura R, Murai T, Shimizu H et al. Efficacy of one week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese Population. Gastroenterol Hepatol 1999;14:317-21.
25. Kayser S, Flury R, Zbinden R, Fried M, Wirth PH. Wirkungsvergleich von lansoprazol/amoxicillin mit omeprazol/amoxicillin zur eradikation von Helicobacter pylori bei Patienten mit Duodenal ulkus. Schweiz Med Wochenschr 1997;127:722-7.
26. Fanti L, Ieri R, Mezzi G, Testoni AP, Passaretti S, Guslandi M. Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. J Clin Gastroenterol 2001;32:45-8.
27. Chang FY, Chiang CY, Tam TN, Ng WW, Lee SD. Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. Gastroenterol Hepatol 1995;10:595-601.
28. Spinzi GC, Bierti L, Bortoli A, Colombo E, Fertita AM, Lanzi GL et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:133-8.
29. Pellicano R, Palmas F, Ponzetto A, Astegiano M, Smedile A, Morgando A et al. Decreasing eradication rate of Helicobacter pylori infection with metronidazole-based triple therapy. A randomized study. Minerva Gastroenterol Dietol 2002;48:265-70.
30. Claessens A, Heerdink E, Eijk J, Lamers C, Leufkens H. Safety review in 10 008 users of lansoprazole in daily practice. Pharmacoepidemiol Drug Saf 2000;9:383-91.
31. Arnold R. Safety of proton pump inhibitors: an overview. Aliment Pharmacol Ther 1994;8:65-70.
32. Freston JW, Rose Pa, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole. The US clinical trial experience. Drug Saf 1999;20:195-205.
33. Nagata K, Takagi E, Tsuda M, Nakazama T, Satoh H, Nakao M et al. Inhibitory action of lansoprazole and Its analogs against Helicobacter Pylori. Inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother 1993;37:769-74.
34. Tsuji S, Kawano S, Higashi T, Mukuda T, Imaizumi T, Tatsumi T et al. Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. J Clin Gastroenterol 1995;20:S1-4.
35. Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishii H. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol 1995;20:S93-6.
36. Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naita Y et al. A new mechanism for anti-inflammatory actions of pump inhibitors-inhibitory effects on neutrophil endothelial cell interactions. Aliment Pharmacol Ther 2000;14 Suppl 1:74-81.
37. Kromer W, Horbach S, Lühmann R. Relative efficacies of gastric proton pump inhibitors. Their clinical and pharmacological basis. Pharmacology 1999;59:57-77.